Napabucasin + Nab-paclitaxel + Gemcitabine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Pancreatic Ductal
Conditions
Carcinoma, Pancreatic Ductal
Trial Timeline
Dec 1, 2016 → Mar 1, 2020
NCT ID
NCT02993731About Napabucasin + Nab-paclitaxel + Gemcitabine
Napabucasin + Nab-paclitaxel + Gemcitabine is a phase 3 stage product being developed by Sumitomo Pharma for Carcinoma, Pancreatic Ductal. The current trial status is completed. This product is registered under clinical trial identifier NCT02993731. Target conditions include Carcinoma, Pancreatic Ductal.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02993731 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoma, Pancreatic Ductal